Literature DB >> 8646683

Invasive breast carcinoma: analysis of dynamic magnetic resonance imaging enhancement features and cell proliferative activity determined by DNA S-phase percentage.

P C Stomper1, S Herman, D L Klippenstein, J S Winston, R M Budnick, C C Stewart.   

Abstract

BACKGROUND: There is little information regarding associations between magnetic resonance imaging (MRI) enhancement and biologic parameters of breast carcinoma. A prospective study was undertaken to correlate MRI dynamic contrast enhancement features with cell proliferative activity, as determined by DNA S-phase percentage.
METHODS: Seventeen patients with invasive breast cancer underwent MRI at 1.5 tesla using a dynamic gadolinium-enhanced spoiled gradient recall echo technique. DNA analysis of samples of the excised lesions was then performed using flow cytometry.
RESULTS: Invasive carcinomas with high DNA S-phase percentages (> or = 6.9%, the median value in this study), a measure of increased cell proliferation, were associated with a peripheral MRI enhancement pattern in 4 of 6 (67%) lesions compared with 0 of 11 carcinomas with lower DNA S-phase percentages (< or = 6.9%) (P = 0.006). There was no significant association between a high DNA S-phase percentage and greater MRI enhancement amplitude, rate, or washout. There was no significant association between aneuploid DNA content and any MRI enhancement feature.
CONCLUSIONS: Increased cell proliferation in invasive breast carcinoma, as determined by high DNA S-phase percentage, is significantly associated with a peripheral MRI enhancement pattern but unrelated to greater MRI enhancement amplitude, rate, or washout.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8646683     DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1844::AID-CNCR13>3.0.CO;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  Review of treatment assessment using DCE-MRI in breast cancer radiation therapy.

Authors:  Chun-Hao Wang; Fang-Fang Yin; Janet Horton; Zheng Chang
Journal:  World J Methodol       Date:  2014-06-26

2.  99mTc-sestamibi uptake and histological malignancy grade in invasive breast carcinoma.

Authors:  Rimma Danielsson; Alejandro Sánchez-Crespo; Anna Pegerfalk; Hanna Grabowska; Stig A Larsson; Beata Boné; Peter Aspelin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-04       Impact factor: 9.236

3.  Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.

Authors:  Ka-Loh Li; Savannah C Partridge; Bonnie N Joe; Jessica E Gibbs; Ying Lu; Laura J Esserman; Nola M Hylton
Journal:  Radiology       Date:  2008-07       Impact factor: 11.105

4.  Invasive breast cancer: correlation of dynamic MR features with prognostic factors.

Authors:  Botond K Szabó; Peter Aspelin; Maria Kristoffersen Wiberg; Tibor Tot; Beata Boné
Journal:  Eur Radiol       Date:  2003-07-26       Impact factor: 5.315

5.  Correlation between high resolution dynamic MR features and prognostic factors in breast cancer.

Authors:  Shin Ho Lee; Nariya Cho; Seung Ja Kim; Joo Hee Cha; Kyung Soo Cho; Eun Sook Ko; Woo Kyung Moon
Journal:  Korean J Radiol       Date:  2008 Jan-Feb       Impact factor: 3.500

6.  Evaluation of tumor angiogenesis with a second-generation US contrast medium in a rat breast tumor model.

Authors:  Eun Young Ko; Sang Hoon Lee; Hak Hee Kim; Sung Moon Kim; Myung Jin Shin; Namkug Kim; Gyungyub Gong
Journal:  Korean J Radiol       Date:  2008 May-Jun       Impact factor: 3.500

7.  Relationship between morphological features and kinetic patterns of enhancement of the dynamic breast magnetic resonance imaging and clinico-pathological and biological factors in invasive breast cancer.

Authors:  Oscar Fernández-Guinea; Alejandro Andicoechea; Luis O González; Salomé González-Reyes; Antonio M Merino; Luis C Hernández; Alfonso López-Muñiz; Paz García-Pravia; Francisco J Vizoso
Journal:  BMC Cancer       Date:  2010-01-08       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.